Previous research demonstrated that bacterial and viral vaccines delivered via the nasal route in rainbow trout at 7 and 28 days were highly efficacious. The question of long-term protection remained; therefore, this study utilized an inactivated Yersinia ruckeri bacterin and a live attenuated infectious hematopoietic necrosis virus (IHNV) vaccine. Juvenile rainbow trout were vaccinated by intraperitoneal (I.P.) or intramuscular (I.M.) injection or by intranasal (I.N.) delivery. When Y. ruckeri-specific lgM antibodies were evaluated, it was found that fish in the I.P. group had significantly higher titers than fish in the PBS-vaccinated group at 6m post-vaccination. The I.N. vaccinated fish had average anti-Y. ruckeri titers that did not differ from either the I.P. or the PBS groups fish. By 12m post immunization, no significant differences were observed in antibody titers to Y. ruckeri across all treatments; however, individual fish were found to have a positive antibody response in the vaccinated groups. Following Y. ruckeri challenge at 6 m, a significant difference in cumulative percent mortality (CPM) was found and the I.P.-vaccinated fish exhibited lower mortality than the PBS controls. Fish vaccinated by I.N. did not show CPM different from the PBS or I.P. groups. For IHNv-specific IgM antibodies, I.M. and I.N. treatments showed no differences to each other in titers at 6 or 12 m. When fish were IHNV challenged at 6 m, vaccination treatment differences were found with respect to CPM. The I.N.-vaccinated fish showed the lowest CPM and differed from the PBS controls. Results indicate that nasal vaccination may induce protection beyond what was initially reported. Although low level IHNV specific IgM titers were detected in sera from I.N.-vaccinated fish, it is likely that additional mucosal (e.g. IgT) or other immune parameters are stimulated and play a greater role in such protection.